| Summary: | Runt-related transcription factor 1 gene (<i>RUNX1</i>), also known as acute myeloid leukaemia 1 protein (AML1), plays a crucial role in the pathogenesis of AML. RUNX1/AML1 is one of the most frequently mutated leukaemias associated with a poor prognosis in AML. Researchers and clinicians can develop personalized medicines and improve diagnosis by identifying the biomarkers associated with mutations. In the current study, we used the genome and transcriptome data from The Cancer Genome Atlas-Acute Myeloid Leukemia (TCGA-AML) cohort. We analysed <i>RUNX1</i> mutant AML patients compared to non-mutant patients using an integrated multi-omics, multi-database analysis of exome, and transcriptomics data. Finally, we identified the gene signature associated with <i>RUNX1</i> mutations, including prognostic genes that significantly influenced the overexpression of <i>RUNX1</i> mutation-associated genes in AML patients. Our results can help to diagnose AML patients with <i>RUNX1</i> mutations at an early stage.
|
|---|